Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Nov;36(11):2458–2461. doi: 10.1128/aac.36.11.2458

Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

J M Kovarik 1, A I Hoepelman 1, J M Smit 1, P A Sips 1, M Rozenberg-Arska 1, J H Glerum 1, J Verhoef 1
PMCID: PMC284353  PMID: 1336948

Abstract

Oral doses of 400 mg of lomefloxacin were administered once daily prior to breakfast to 10 middle-aged to elderly hospitalized patients with chronic obstructive pulmonary disease during treatment for bronchopulmonary infections. Serial plasma and sputum samples and fractional urine samples were obtained over a steady-state dosing interval. Lomefloxacin concentrations were determined in duplicate by a validated agar well diffusion microbiological assay. The maximum plasma lomefloxacin concentration (4.5 +/- 1.8 mg/liter), the time of occurrence of the maximum concentration (1.7 +/- 1.6 h), and the apparent volume of distribution associated with the terminal phase (2.19 +/- 1.05 liter/kg) were comparable to the values reported for healthy, young volunteers. Compared with the data reported for young adults, the elimination half-life (12.7 +/- 4.67 h) was longer and the apparent total body clearance (132 +/- 36.6 ml/min/1.73 m2) was lower in middle-aged to elderly patients. These differences were most likely attributable to age-related decreases in renal function, as evidenced by the lower lomefloxacin renal clearance (70.3 +/- 33.5 ml/min) in patients. The presence of acute respiratory infection per se did not appear to alter lomefloxacin pharmacokinetics. The peak lomefloxacin concentration in purulent, expectorated sputum samples of 4.3 +/- 1.2 mg/liter occurred 3.1 +/- 1.7 h after dose administration and subsequently declined to 1.7 +/- 0.5 mg/liter at the end of the 24-h dosing interval. The percent penetration into sputum, as assessed by comparing the area under the curve for sputum and plasma samples, was 120 +/- 39.8 (range, 70 to 185). The steady-state lomefloxacin concentrations in plasma and sputum samples from ill, older patients were in excess of the MICs for 90% of the strains tested of common, susceptible respiratory pathogens over most of the dosing interval.

Full text

PDF
2458

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin D. R., Honeybourne D., Andrews J. M., Ashby J. P., Wise R. Concentrations of oral lomefloxacin in serum and bronchial mucosa. Antimicrob Agents Chemother. 1990 Jun;34(6):1017–1019. doi: 10.1128/aac.34.6.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baldwin D. R., Honeybourne D., Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother. 1992 Jun;36(6):1171–1175. doi: 10.1128/aac.36.6.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chin N. X., Novelli A., Neu H. C. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones. Antimicrob Agents Chemother. 1988 May;32(5):656–662. doi: 10.1128/aac.32.5.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davies B. I., Maesen F. P., Teengs J. P., Baur C. The quinolones in chronic bronchitis. Pharm Weekbl Sci. 1986 Feb 21;8(1):53–59. doi: 10.1007/BF01975481. [DOI] [PubMed] [Google Scholar]
  6. Drusano G. L., Plaisance K. I., Forrest A., Bustamante C., Devlin A., Standiford H. C., Wade J. C. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Sep;31(9):1420–1422. doi: 10.1128/aac.31.9.1420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ganzinger U., Kleinberger G., Lenz K., Schatz F., Laggner A., Grimm G. Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis. Int J Clin Pharmacol Ther Toxicol. 1987 Jul;25(7):354–362. [PubMed] [Google Scholar]
  8. Gerding D. N., Hitt J. A. Tissue penetration of the new quinolones in humans. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1046–S1057. doi: 10.1093/clinids/11.supplement_5.s1046. [DOI] [PubMed] [Google Scholar]
  9. Gros I., Carbon C. Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days. Antimicrob Agents Chemother. 1990 Jan;34(1):150–152. doi: 10.1128/aac.34.1.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Janicke D. M., Cafarell R. F., Parker S. W., Apicella M. A., Jusko W. J. Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother. 1985 Jan;27(1):16–20. doi: 10.1128/aac.27.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mazzulli T., Simor A. E., Jaeger R., Fuller S., Low D. E. Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1990 Mar;34(3):467–469. doi: 10.1128/aac.34.3.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Neu H. C. Clinical use of the quinolones. Lancet. 1987 Dec 5;2(8571):1319–1322. doi: 10.1016/s0140-6736(87)91205-0. [DOI] [PubMed] [Google Scholar]
  13. Nix D. E., Norman A., Schentag J. J. Effect of lomefloxacin on theophylline pharmacokinetics. Antimicrob Agents Chemother. 1989 Jul;33(7):1006–1008. doi: 10.1128/aac.33.7.1006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pennington J. E. Penetration of antibiotics into respiratory secretions. Rev Infect Dis. 1981 Jan-Feb;3(1):67–73. doi: 10.1093/clinids/3.1.67. [DOI] [PubMed] [Google Scholar]
  15. Ramirez J., O'Neill E. F. Endobronchial Polymyxin B: experimental observations in chronic bronchitis. Chest. 1970 Oct;58(4):352–357. doi: 10.1378/chest.58.4.352. [DOI] [PubMed] [Google Scholar]
  16. Sonne J., Døssing M., Loft S., Andreasen P. B. Antipyrine clearance in pneumonia. Clin Pharmacol Ther. 1985 Jun;37(6):701–704. doi: 10.1038/clpt.1985.117. [DOI] [PubMed] [Google Scholar]
  17. Wadworth A. N., Goa K. L. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1991 Dec;42(6):1018–1060. doi: 10.2165/00003495-199142060-00009. [DOI] [PubMed] [Google Scholar]
  18. Wise R., Andrews J. M., Ashby J. P., Matthews R. S. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother. 1988 May;32(5):617–622. doi: 10.1128/aac.32.5.617. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES